Psychiatric Care and Research Center
O'Fallon, Missouri 63368-8223
3 studies enrolling now · 24 studies all time
What they study most
Attention Deficit Hyperactivity Disorder (ADHD), Attention-Deficit/Hyperactivity Disorder, Bipolar Depression, Bipolar Disorder, Bipolar I Disorder, Bipolar II Disorder, Borderline Personality Disorder, Depressive Disorder, Major, Intermittent Explosive Disorder, Major Depressive Disorder, Obsessive Compulsive Disorder, Obsessive-Compulsive Disorder
Studies at this site
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) — Recruiting now
- A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) — Recruiting now
- An Open-Label Study of Azetukalner in Major Depressive Disorder — Enrolling by invitation
- A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in Obsessive-Compulsive Disorder — Completed
- A Study to Test Different Doses of BI 1569912 in People With Depression — Completed
- Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder — Completed
- Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder — Stopped early
- Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disorder — Completed
- A Study to Test the Effect of Different Doses of BI 1358894 and Quetiapine in People With Depression — Completed
- A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder — Completed
- Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) — Stopped early
- Safety, Tolerability and Activity of SRX246 in Adults With Intermittent Explosive Disorder — Completed
- Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder — Stopped early
- SPD489 Low Dose and High Dose Ranges When Added to Stable Doses of Antipsychotic Medications in Clinically Stable Adults With Negative Symptoms of Schizophrenia — Stopped early
- Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD) — Completed
- Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) — Completed
- Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
- Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
- A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) — Completed
- A Twelve Week, Open Label Extension Study in Patients With Schizophrenia — Completed
- A Study of Intermittent Doses of CERC-301 in MDD — Completed
- PEARL Schizophrenia Maintenance — Completed
- Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder — Completed